We invite feedback on the operation and impact of the human medicines and medical devices legislation as part of a statutory review required under the Medicines and Medical Devices Act 2021.
Similar Posts
Clinical trials: Non-investigational medicinal products
Guidance on using non-investigational medicinal products in a clinical trial.
Medicines regulator approves up to 7.2mg dose of semaglutide (Wegovy) for patients with obesity only
The Medicines and Healthcare products Regulatory Agency (MHRA) approved a maximum dose of up to 7.2mg per week of semaglutide (Wegovy) on 6 January 2026.
MHRA Safety Roundup: September 2025
Summary of the latest safety advice for medicines and medical device users
Decision: Advertising Investigations: August 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Decision: Marketing authorisations granted in 2025
Marketing authorisations granted in 2025.
Guidance: Risk minimisation measures for medicines
Guidance for healthcare professionals on risk minimisation options for medicines.